D4S Stock Overview
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for D4S from our risk checks.
Daiichi Sankyo Company, Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥30.40 |
| 52 Week High | JP¥34.48 |
| 52 Week Low | JP¥22.35 |
| Beta | 0.29 |
| 1 Month Change | 2.05% |
| 3 Month Change | 12.97% |
| 1 Year Change | -0.98% |
| 3 Year Change | 41.92% |
| 5 Year Change | 110.09% |
| Change since IPO | 519.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| D4S | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 9.8% | 1.3% | 1.1% |
| 1Y | -1.0% | -28.6% | 1.9% |
Return vs Industry: D4S exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: D4S underperformed the German Market which returned 2% over the past year.
Price Volatility
| D4S volatility | |
|---|---|
| D4S Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: D4S has not had significant price volatility in the past 3 months.
Volatility Over Time: D4S's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1899 | 17,435 | Sunao Manabe | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol.
Daiichi Sankyo Company, Limited Fundamentals Summary
| D4S fundamental statistics | |
|---|---|
| Market cap | €57.42b |
| Earnings (TTM) | €1.20b |
| Revenue (TTM) | €9.57b |
47.9x
P/E Ratio6.0x
P/S RatioIs D4S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D4S income statement (TTM) | |
|---|---|
| Revenue | JP¥1.60t |
| Cost of Revenue | JP¥415.32b |
| Gross Profit | JP¥1.19t |
| Other Expenses | JP¥985.64b |
| Earnings | JP¥200.73b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 104.68 |
| Gross Margin | 74.07% |
| Net Profit Margin | 12.53% |
| Debt/Equity Ratio | 6.0% |
How did D4S perform over the long term?
See historical performance and comparison